Disclosed in the present application is an atomization drug delivery device. The device comprises: a container; a housing comprising an inner housing portion and an upper housing portion capable of rotating relative to the inner housing portion, wherein when the upper housing portion completes one full rotation relative to the inner housing portion, fluid in the container is extracted for one atomization cycle; and an indicator comprising a threaded rod rotatably supported on the inner housing portion and an indication element for indicating the number of times of atomization by means of its axial position on the threaded rod, wherein the threaded rod comprises one transmission gear, the upper housing portion is provided with a driving portion, and when the driving portion rotates relative to the inner housing portion along with the upper housing portion and engages the transmission gear, the threaded rod is driven to rotate, thereby causing the indication element to move in the axial direction. The transmission gear comprises P teeth, and P is configured as at least three; the driving portion is configured as at most two single-tooth members arranged opposite to each other, such that P or 2P rotational movements cause the indication element to advance by one stroke in the axial direction of the threaded rod. This allows the number of times of atomization of the atomization drug delivery device to reach P times or 2P times of the total number of strokes provided by the threaded rod in the axial direction.
Disclosed are an atomizer for a fluid and a method for conveying and atomizing a fluid. The atomizer includes: a cartridge for accommodating multiple doses of the fluid; a delivery mechanism movable from an initial position to a tensioning position for withdrawal of a medication dosage of the fluid from the cartridge when the atomizer is tensioned, and movable from the tensioning position to the initial position for atomization of the medication dosage of the fluid when the atomizer is activated; a pre-determined amount of the fluid is atomized by a temporary rebound motion of the delivery mechanism during its movement from the initial position to the tensioning position, and the medication dosage is a single medication dose, and the pre-determined amount is less than the medication dosage.
A61J 3/02 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration la forme de poudres
A61M 11/00 - Pulvérisateurs ou vaporisateurs spécialement destinés à des usages médicaux
Massage apparatus; Vibromassage apparatus; Electric massage therapy guns; Massaging apparatus for personal use; Electric massage apparatus for household use; Massage apparatus for neck and shoulders
4.
MEDICINE-POWDER MEASURING ROD, MEDICINE-POWDER MEASURING ROD ASSEMBLY, AND MEDICINE-POWDER MEASURING SYSTEM
Disclosed in the present application are a medicine-powder measuring rod, a medicine-powder measuring rod assembly, and a medicine-powder measuring system. The medicine-powder measuring rod comprises: a rod portion, which comprises a rod portion body, an operating section located at the proximal end of the rod portion body, and a measuring section located at the distal end of the rod portion body; and a dose tank, which is formed on the circumferential surface of the measuring section and is configured to accommodate a preset amount of medicine powder. When the rod is transferred by means of the operating section so as to be butt-joined to a simulated inhalation device, the dose tank comes into communication with a chamber inlet of the simulated inhalation device, such that an airflow carries the medicine powder in the dose tank to pass through the chamber inlet to a chamber outlet of the simulated inhalation device, thereby completing a test operation.
Dose counters (5) and an inhaler, the dose counters being suitable for an inhaler. A dose counter (5) comprises: an actuating mechanism (50) configured to be driven to move towards a distal end; and a counting component (51) comprising a first counting unit (510) and a second counting unit (511). When the actuating mechanism (50) moves towards the distal end, the first counting unit (510) is driven by the actuating mechanism (50) to count a first group of numbers. When the first counting unit (510) has counted a preset number of times, the second counting unit (511) is driven to count a second group of numbers. Thus, the first counting unit (510) and the second counting unit (511) cooperate with each other to provide a visual digital indication of the number of times that an inhaler has been used.
A breath-actuated inhaler. The inhaler comprises a main housing (1), a canister (2), and a force holding unit (4), wherein a mouthpiece (10) is provided at the distal end of the main housing (1); the canister (2) stores a drug solution and is disposed in the axial direction of the main housing (1); and the force holding unit (4) is attached to the main housing (1) and engaged with the canister, the force holding unit (4) comprises an upper shell (40), an air intake structure (48) being provided at the proximal end of the upper shell (40), and the air intake structure (48) and the mouthpiece (10) forming a gas circulation path such that the force holding unit (4) activates the canister (2) in response to the inhalation by a user. The air intake structure (48) comprises at least two holes (480) having main openings, the at least two holes (480) being connected end to end in a circular arrangement at the proximal end of the upper shell (40), thus preventing the main openings of all the holes from being completely covered by the user's finger when placed on the end face of the proximal end during inhalation.
Disclosed in the present application are a nebulizer for a fluid, and a method for delivering and atomizing a fluid. The nebulizer comprises: a container, which holds multiple doses of the fluid; and a delivery mechanism, which is configured to move from an initial position to a tensioning position when the nebulizer is tensioned, so as to draw a dose of the fluid from the container, and is configured to move from the tensioning position to the initial position when the nebulizer is started, so as to atomize the dose of the fluid, wherein during the movement of the delivery mechanism from the initial position to the tensioning position, a preset amount of the fluid is atomized by means of a temporary rebound motion, the dose being a single dose, and the preset amount being smaller than the dose.
22 receptor agonistic activity, and an isomer or pharmaceutically acceptable salt thereof, wherein each group is as defined in the description. The compound of formula (I), and the isomer or pharmaceutically acceptable salt thereof can be ideally converted into a carboxylic acid active metabolite in the lung, have physicochemical properties more suitable for pulmonary administration, and can stay in the lung for a long time and slowly release the carboxylic acid active metabolite with an effective concentration. According to the compound of formula (I), and the isomer or pharmaceutically acceptable salt thereof provided by the present invention for use in transpulmonary administration, the administration dosage can be greatly reduced, a lower administration frequency and a wider therapy window are provided, the systematic side effect is reduced, the food effect is avoided, the safety of drugs and the tolerance of patients to the drugs are greatly increased, thereby providing a new treatment choice for patients suffering from pulmonary hypertension.
RUIJIN HOSPITAL, SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE (Chine)
Inventeur(s)
Qu, Jieming
Zhao, Jingya
Xu, Lin
Che, Lin
Li, Xiujuan
Quan, Mengxue
Liang, Bill Wenqing
Abrégé
The present invention relates to the field of chemical pharmaceuticals and provides use of an (-)-epigallocatechin gallate (EGCG) compound. The present invention particularly relates to use of an EGCG compound in the preparation of an inhalation drug for preventing and/or treating pulmonary fibrosis diseases, an inhalable pharmaceutical composition for preventing and/or treating pulmonary fibrosis diseases, and a method for preventing and/or treating pulmonary fibrosis diseases. In the use, the EGCG compound is EGCG or a pharmaceutically acceptable salt thereof, an ester thereof, a hydrate thereof, or a solvate thereof. The drug/pharmaceutical composition taking the EGCG compound as an active ingredient provided by the embodiment is used as an inhalable drug for preventing and treating pulmonary fibrosis, such that an administration dosage can be greatly reduced, a relatively wide treatment window is provided, and a relatively slight adverse reaction and a relatively low administration frequency are achieved, thereby providing a new treatment choice for a pulmonary fibrosis patient.
Disclosed is an inhalation device, which, by means of a simplified structure, reduces the manufacturing difficulty and cost while ensuring the use effect. In the inhalation device of the present application, a filter member closely fits a capsule insertion port, and when a mouthpiece is snap-fitted on a deck, a mesh portion is integrally located in a capsule chamber. Therefore, when pharmaceutical powder is inhaled, airflow can better pass through the mesh portion under the action of a negative pressure to flow in an ideal flow direction, thereby ensuring effective inhalation of the pharmaceutical powder.
An atomization comb, comprising: a main body (3), a vapor channel (11) being provided in the main body (3); comb teeth (4), the comb teeth (4) being connected to the main body (3); and a cartridge (2), the cartridge (2) being detachably connected to an outer side of the main body (3), and the cartridge (2) comprising a bottle (6) and an atomization device (7). Active ingredients in a care solution can be atomized to form particles with a particle size of 5-10 microns so as to effectively penetrate the scalp, hair roots and hair ends. The finer particles facilitate more uniform attachment and deeper penetration, resulting in faster action. In addition, combing hair with the comb teeth (4) sufficiently detangles the hair to create gaps such that tiny droplets penetrate each affected part by means of the comb teeth (4), so that the active ingredients in the care solution can be fully and uniformly transferred from the scalp and hair roots to the hair ends of a patient, so as to solve many problems regarding the scalp, hair follicles, hair roots and hair of the patient.
Disclosed is an inhalation device, which, by means of a simplified structure, reduces the manufacturing difficulty and cost, and ensures the use effect. In the inhalation device, a filter member closely fits to a capsule placement opening, and when a mouthpiece is clamped to a cover plate, a mesh portion is integrally located in a capsule compartment. Therefore, when a medicinal powder is inhaled, airflow can better pass through the mesh portion under the action of a negative pressure to flow in an ideal flow direction, thereby ensuring the medicinal powder to be effectively inhaled.
A pharmaceutical inhalation aerosol and a preparation method therefor. The preparation method comprises the following steps: (1) mixing glycopyrronium bromide coarse powder with indacaterol fine powder, or glycopyrronium bromide coarse powder with indacaterol coarse powder, or glycopyrronium bromide fine powder with indacaterol coarse powder in proportion to obtain a glycopyrronium bromide and indacaterol mixture; (2) micronizing, by a crushing device under pressure, the glycopyrronium bromide and indacaterol mixture prepared in step (1) to obtain a micronized glycopyrronium bromide and indacaterol mixture; and (3) adding the micronized glycopyrronium bromide and indacaterol mixture prepared in step (2) to an aluminum can, performing valve sealing, and filling with a propellant. In the glycopyrronium bromide/indacaterol compound inhalation aerosol prepared by the method, the effective deposition rate of glycopyrronium bromide is significantly improved, and the degree of co-deposition of glycopyrronium bromide and indacaterol is high. The prepared inhalation aerosol is convenient to carry and low in price, has higher medication compliance compared with an inhalation powder aerosol, and is more widely used than a nebulizer.
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
Chronic obstructive pulmonary disease is a type of chronic bronchitis and (or) emphysema having the characteristic of airflow obstruction, which is debilitating and has a high mortality rate. On the basis of a synergistic effect, compound drugs have been widely applied to treat said disease. In order to achieve the best therapeutic effect, two active ingredients should exhibit similar deposition behavior in the human lungs and should be delivered to an affected area to have a medicinal effect. Compared with the inhalation dosage forms of dry powder and atomization, the convenience and safety of patients when using a medicine is considered, and a method for preparing a micropowder of the active pharmaceutical ingredients of a compound inhalation aerosol is provided. The glycopyrronium bromide and indacaterol compound inhalation aerosol obtained by using the present preparation method can effectively increase the effective site deposition rate of glycopyrronium bromide, and can improve the degree of co-deposition between the two active ingredients. Processing is simple for the micropowder mixture of the active pharmaceutical ingredients of glycopyrronium bromide and indacaterol prepared by using the present preparation method as well as for a compound inhalation aerosol thereof, and the FPF of the active ingredients is significantly increased.
A61K 9/72 - Préparations médicinales caractérisées par un aspect particulier à fumer ou inhaler
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
A pharmaceutical inhalation aerosol and a preparation method therefor. The preparation method comprises the following steps: (1) mixing glycopyrronium bromide coarse powder with indacaterol fine powder, or glycopyrronium bromide coarse powder with indacaterol coarse powder, or glycopyrronium bromide fine powder with indacaterol coarse powder in proportion to obtain a glycopyrronium bromide and indacaterol mixture; (2) micronizing, by a crushing device under pressure, the glycopyrronium bromide and indacaterol mixture prepared in step (1) to obtain a micronized glycopyrronium bromide and indacaterol mixture; and (3) adding the micronized glycopyrronium bromide and indacaterol mixture prepared in step (2) to an aluminum can, performing valve sealing, and filling with a propellant. In the glycopyrronium bromide/indacaterol compound inhalation aerosol prepared by the method, the effective deposition rate of glycopyrronium bromide is significantly improved, and the degree of co-deposition of glycopyrronium bromide and indacaterol is high. The prepared inhalation aerosol is convenient to carry and low in price, has higher medication compliance compared with an inhalation powder aerosol, and is more widely used than a nebulizer.
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Antiseptics; vitamin preparations; drugs for medical purposes; medicines for human purposes; pharmaceutical products for treating respiratory diseases; pharmaceutical preparations for treating respiratory diseases; cough medicine; anti-tussive expectorants; antivirals; dietetic foods adapted for medical purposes; dietetic beverages adapted for medical purposes. Instrument cases for use by doctors; insufflators; cases fitted for medical instruments; respirators for artificial respiration; apparatus for artificial respiration; respiratory masks for artificial respiration; chambers for inhalers; medical apparatus for facilitating the inhalation of pharmaceutical preparations; medical apparatus for introducing pharmaceutical preparations into the human body; nebulizers for medical purposes.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Medicines for human purposes; balsamic preparations for medical purposes; drugs for medical purposes; disinfectants for hygiene purposes; antibiotics; vaccines against pneumococcal infections; pharmaceutical preparations for treating asthma; pharmaceutical preparations for treating hypertension; preparations for the treatment of asthma; Vitamin preparations. Instrument cases for use by doctors; diagnostic apparatus for medical purposes; testing apparatus for medical purposes; medical apparatus and instruments; cases fitted for medical instruments; otolaryngology instruments; galvanic therapeutic appliances; abdominal pads for medical use; bandages for joints, anatomical; suture materials.
